Great Point Partners Llc
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$435.1M
Q ending 2026-03-31
Prior quarter
$308.4M
Q ending 2025-12-31
Change
+41.1% QoQ · +130.5% YoY
Positions
42
reported holdings
Largest positions
All 42 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Apogee Therapeutics Inc | APGE | Shares | $31.5M | 374K |
| Vor Biopharma Inc | VOR | Shares | $31.2M | 1.8M |
| Zura Bio Ltd | Shares | $25.1M | 4.2M | |
| Amylyx Pharmaceuticals Inc | AMLX | Shares | $24.3M | 1.8M |
| Immunitybio Inc | IBRX | Put | $23.0M | 3.0M |
| Nektar Therapeutics | NKTR | Shares | $22.8M | 316K |
| Sol-Gel Technologies Ltd | Shares | $21.7M | 274K | |
| Alumis Inc | ALMS | Shares | $18.9M | 856K |
| Bright Minds Biosciences Inc | DRUG | Shares | $16.1M | 220K |
| Annexon Inc | ANNX | Shares | $13.8M | 2.5M |
| Kalvista Pharmaceuticals Inc | 4XC1 | Shares | $13.6M | 675K |
| Immunovant Inc | IMVT | Shares | $13.6M | 546K |
| Jade Biosciences Inc | JBIO | Shares | $13.6M | 964K |
| Contineum Therapeutics Inc | CTNM | Shares | $10.5M | 800K |
| Zenas Biopharma Inc | ZBIO | Shares | $10.2M | 524K |
| Neurogene Inc | NGNE | Shares | $10.1M | 500K |
| Moonlake Immunotherapeutics | MLTX | Shares | $9.3M | 500K |
| Climb Bio Inc | CLYM | Shares | $9.1M | 1.3M |
| Oruka Therapeutics Inc | ORKA | Shares | $9.0M | 183K |
| Eupraxia Pharmaceuticals Inc | EPRX | Shares | $8.7M | 1.2M |
| Vera Therapeutics Inc | VERA | Shares | $8.0M | 199K |
| Evommune Inc | EVMN | Shares | $7.5M | 325K |
| Lb Pharmaceuticals Inc | LBRX | Shares | $7.4M | 300K |
| Compass Therapeutics Inc | CMPX | Shares | $7.1M | 1.4M |
| Scynexis Inc | SCYXEUR | Shares | $6.9M | 7.6M |
| Palisade Bio Inc | PALI | Shares | $6.0M | 3.4M |
| Context Therapeutics Inc | CNTX | Shares | $5.9M | 2.2M |
| Relmada Therapeutics Inc | RLMD | Shares | $5.9M | 842K |
| Silence Therapeutics Plc | SLN | Shares | $5.4M | 1.0M |
| Unicycive Therapeutics Inc | UNCY | Shares | $5.2M | 797K |
| Tenax Therapeutics Inc | TENX | Shares | $5.2M | 327K |
| Promis Neurosciences Inc | PMN | Shares | $4.7M | 371K |
| Cullinan Therapeutics Inc | CGEM | Shares | $4.3M | 300K |
| Immix Biopharma Inc | IMMX | Shares | $3.2M | 350K |
| Rezolute Inc | RZLT | Shares | $2.9M | 952K |
| Pharvaris N V | Shares | $2.3M | 83K | |
| Humacyte Inc | HUMA | Shares | $2.3M | 3.8M |
| Galectin Therapeutics Inc | GALT | Call | $2.2M | 800K |
| Avalo Therapeutics Inc | AVTX | Shares | $1.9M | 125K |
| Alkermes Plc | Shares | $1.8M | 50K | |
| Anavex Life Sciences Corp | AVXL | Call | $1.6M | 521K |
| Opus Genetics Inc | IRD | Shares | $1.5M | 324K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.